Stockscreener 앱 받기
36.85
5.02%
1.76
전일 마감가:
$35.09
열려 있는:
$36.105
하루 거래량:
3.44M
Relative Volume:
1.54
시가총액:
$10.31B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
23.62
EPS:
1.56
순현금흐름:
$404.94M
1주 성능:
+5.29%
1개월 성능:
+1.15%
6개월 성능:
+39.95%
1년 성능:
+77.85%
1일 변동 폭
$35.88
$37.05
1주일 범위
$34.01
$37.05
52주 변동 폭
$20.14
$37.59
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.85 | 10.31B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (EXEL) Stock Jumps Amid New Share Buyback Announcement - GuruFocus.com
Why Exelixis Stock Trounced the Market on Thursday - Nasdaq
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - AOL
Why Exelixis Shares Are Skyrocketing: A Story of Triumph and Strategy - Jomfruland.net
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point - Yahoo Finance
Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio! - Smartkarma
Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours - Marketscreener.com
Exelixis Approves Additional $500 Mln Stock Buyback Program - Nasdaq
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - The Bakersfield Californian
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Nasdaq
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 By Investing.com - Investing.com South Africa
Exelixis director George Poste sells $551,462 in stock By Investing.com - Investing.com Australia
Exelixis director Mary Beckerle sells $425,878 in stock By Investing.com - Investing.com Australia
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock - Investing.com India
Exelixis director Mary Beckerle sells $425,878 in stock - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock By Investing.com - Investing.com Nigeria
Exelixis Executives Sell Shares in February Transactions - TradingView
Exelixis looks to next-gen cancer drug as Cabometyx underwhelms again - PharmaLive
Exelixis's SWOT analysis: cabo patent win boosts stock outlook By Investing.com - Investing.com Nigeria
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? - MSN
Exelixis's SWOT analysis: cabo patent win boosts stock outlook - Investing.com
Exelixis falls after ASCO releases colorectal cancer data - MSN
International Markets and Exelixis (EXEL): A Deep Dive for Investors - Nasdaq
Five-year results see Exelixis’ RCC therapy extending overall survival - Yahoo Finance
Exelixis stock rating cut by Oppenheimer, price target to $33 from $41 - MSN
JMP Securities maintains Exelixis stock with $41 target - MSN
Exelixis Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by StockNews.com - MarketBeat
State of Alaska Department of Revenue Decreases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler Increases Exelixis (NASDAQ:EXEL) Price Target to $38.00 - MarketBeat
Sapient Capital LLC Invests $256,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates - MSN
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX - Business Wire
Exelixis (NASDAQ:EXEL) Given New $29.00 Price Target at Barclays - MarketBeat
Q3 Earnings Forecast for Exelixis Issued By Leerink Partnrs - MarketBeat
Citigroup Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Polaris Capital Management LLC Sells 16,900 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Empowered Funds LLC Takes $7.46 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
EXELExelixis Inc Latest Stock News & Market Updates - StockTitan
Stifel Nicolaus Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Stifel raises Exelixis stock price target to $36, maintains hold - MSN
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Exelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - BioSpace
FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock holds firm with $41 target from JMP Securities - MSN
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress - MSN
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Exelixis Inc 주식 (EXEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Beckerle Mary C | Director |
Feb 14 '25 |
Sale |
34.88 |
12,210 |
425,878 |
30,406 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Option Exercise |
20.50 |
15,874 |
325,417 |
184,894 |
| POSTE GEORGE | Director |
Feb 14 '25 |
Sale |
34.74 |
15,874 |
551,463 |
169,020 |
| Freire Maria C | Director |
Feb 14 '25 |
Option Exercise |
21.52 |
44,114 |
949,521 |
135,121 |
| Freire Maria C | Director |
Feb 14 '25 |
Sale |
34.94 |
44,114 |
1,541,343 |
91,007 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Option Exercise |
23.24 |
7,712 |
179,227 |
41,974 |
| Eckhardt Sue Gail | Director |
Feb 14 '25 |
Sale |
35.02 |
11,568 |
405,111 |
30,406 |
0.27%
3.05%
자본화:
|
볼륨(24시간):